AW
AKBA icon

Alpha Windward’s Akebia Therapeutics AKBA Stock Holding History

Alpha Windward’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-41,760
Closed -$105K – 17
2020
Q3 		$105K Buy
41,760
+15,060
+56% +$132K 0.08% 277
2020
Q2 		$363K Buy
+26,700
New +$276K 0.28% 143

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Alpha Windward's AKBA Position: Q4 2020 in Review

Alpha Windward sold out of Akebia Therapeutics (AKBA) in Q4 2020, closing a stake of 41,760 shares — an estimated $105K sold.

Alpha Windward first reported a position in AKBA in Q2 2020 and held it in 2 quarters. The position peaked at $363K in Q2 2020. 143 funds tracked by Wall St. Rank hold AKBA as of Q4 2020.

  • Alpha Windward reported no remaining Akebia Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Alpha Windward sold 41,760 Akebia Therapeutics shares in Q4 2020, an estimated $105K.
  • Alpha Windward first reported a position in Akebia Therapeutics in Q2 2020 and held it in 2 quarters.
  • Alpha Windward's Akebia Therapeutics position peaked at $363K in Q2 2020.
  • 143 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2020.

Based on Alpha Windward's 13F filing for Q4 2020.